Lucia Lopalco

Lucia Lopalco

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID.

The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID.

Journal: Frontiers in immunology
Published: February 02, 2024

Editorial: Mucosal immunity to HIV and SARS-CoV-2 infection and vaccination.

Editorial: Mucosal immunity to HIV and SARS-CoV-2 infection and vaccination.

Journal: Frontiers in immunology
Published: April 06, 2023

Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms.

Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms.

Journal: Vaccines
Published: November 04, 2022

Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis.

Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis.

Journal: Frontiers in immunology
Published: December 23, 2021

Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection.

Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection.

Journal: Cells
Published: November 25, 2021

SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals.

SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals.

Journal: EBioMedicine
Published: November 03, 2021

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2.

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2.

Journal: Journal of translational medicine
Published: October 29, 2021

Native CGRP Neuropeptide and Its Stable Analogue SAX, But Not CGRP Peptide Fragments, Inhibit Mucosal HIV-1 Transmission.

Native CGRP Neuropeptide and Its Stable Analogue SAX, But Not CGRP Peptide Fragments, Inhibit Mucosal HIV-1 Transmission.

Journal: Frontiers in immunology
Published: September 29, 2021

Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.

Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.

Journal: Frontiers in immunology
Published: September 07, 2021

HIV-1 Env Does Not Enable the Development of Protective Broadly Neutralizing Antibodies in an Experimental Autoimmune Encephalomyelitis Mouse Model.

HIV-1 Env Does Not Enable the Development of Protective Broadly Neutralizing Antibodies in an Experimental Autoimmune Encephalomyelitis Mouse Model.

Journal: Frontiers in immunology
Published: September 06, 2021

Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve.

Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve.

Journal: Communications medicine
Published: June 03, 2021

Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients.

Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients.

Journal: AIDS (London, England)
Published: May 16, 2021
Showing 1-12 of 37

Last Updated: 09/26/2026